Willemin, Marie-Emilie http://orcid.org/0000-0002-1974-1170
Zannikos, Peter
Mannens, Geert
de Zwart, Loeckie
Snoeys, Jan
Funding for this research was provided by:
Janssen Research and Development
Article History
Accepted: 15 March 2022
First Online: 17 May 2022
Declarations
:
: This study was funded by Janssen Research & Development, LLC.
: Marie-Emilie Willemin, Peter Zannikos, Geert Mannens, Loeckie de Zwart, and Jan Snoeys are employees of Janssen Research & Development, LLC, and may hold company stocks or stock options.
: Institutional review boards or independent ethics committees approved the study protocols of all primary pharmacokinetic and DDI studies. The studies were conducted in accordance with the ethical principles of the Declaration of Helsinki, good clinical practice, and applicable regulatory requirements.
: All participants provided written consent to participate
: All authors read and approved the manuscript for publication, agreed on the journal to which the article was submitted, and agreed to be accountable for all aspects of the work.
: The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at ExternalRef removed. Requests for access to the study data can be submitted through Yale Open Data Access Project site at ExternalRef removed.
: Not applicable.
: All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.